-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

Benzinga·03/20/2026 10:20:20
Listen to the news
BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.